531 related articles for article (PubMed ID: 27943171)
1. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of spiro-tetrahydrothiopyran-oxindoles by Michael-aldol cascade reactions: discovery of potential P53-MDM2 inhibitors with good antitumor activity.
Wang S; Chen S; Guo Z; He S; Zhang F; Liu X; Chen W; Zhang S; Sheng C
Org Biomol Chem; 2018 Jan; 16(4):625-634. PubMed ID: 29302672
[TBL] [Abstract][Full Text] [Related]
3. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of p53-Murine Double Minute 2 (MDM2) Interactions with 3,3'-Spirocyclopentene Oxindole Derivatives.
Gicquel M; Gomez C; Garcia Alvarez MC; Pamlard O; Guérineau V; Jacquet E; Bignon J; Voituriez A; Marinetti A
J Med Chem; 2018 Oct; 61(20):9386-9392. PubMed ID: 30221935
[TBL] [Abstract][Full Text] [Related]
5. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction.
Ding K; Lu Y; Nikolovska-Coleska Z; Wang G; Qiu S; Shangary S; Gao W; Qin D; Stuckey J; Krajewski K; Roller PP; Wang S
J Med Chem; 2006 Jun; 49(12):3432-5. PubMed ID: 16759082
[TBL] [Abstract][Full Text] [Related]
6. Molecular modeling approaches in the discovery of new drugs for anti-cancer therapy: the investigation of p53-MDM2 interaction and its inhibition by small molecules.
Lauria A; Tutone M; Ippolito M; Pantano L; Almerico AM
Curr Med Chem; 2010; 17(28):3142-54. PubMed ID: 20666726
[TBL] [Abstract][Full Text] [Related]
7. Organocatalytic Asymmetric Synthesis of Spiro-oxindole Piperidine Derivatives That Reduce Cancer Cell Proliferation by Inhibiting MDM2-p53 Interaction.
Yang MC; Peng C; Huang H; Yang L; He XH; Huang W; Cui HL; He G; Han B
Org Lett; 2017 Dec; 19(24):6752-6755. PubMed ID: 29210587
[TBL] [Abstract][Full Text] [Related]
8. A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice.
Zhao Y; Yu S; Sun W; Liu L; Lu J; McEachern D; Shargary S; Bernard D; Li X; Zhao T; Zou P; Sun D; Wang S
J Med Chem; 2013 Jul; 56(13):5553-61. PubMed ID: 23786219
[TBL] [Abstract][Full Text] [Related]
9. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
10. Design of chemically stable, potent, and efficacious MDM2 inhibitors that exploit the retro-mannich ring-opening-cyclization reaction mechanism in spiro-oxindoles.
Aguilar A; Sun W; Liu L; Lu J; McEachern D; Bernard D; Deschamps JR; Wang S
J Med Chem; 2014 Dec; 57(24):10486-98. PubMed ID: 25496041
[TBL] [Abstract][Full Text] [Related]
11. Medicinal Chemistry Strategies to Disrupt the p53-MDM2/MDMX Interaction.
Lemos A; Leão M; Soares J; Palmeira A; Pinto M; Saraiva L; Sousa ME
Med Res Rev; 2016 Sep; 36(5):789-844. PubMed ID: 27302609
[TBL] [Abstract][Full Text] [Related]
12. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
13. One-pot synthesis of spiro(indoline-3,4'-pyrazolo[3,4-b]pyridine)-5'-carbonitriles as p53-MDM2 interaction inhibitors.
Ibrahim HS; Eldehna WM; Fallacara AL; Ahmed ER; Ghabbour HA; Elaasser MM; Botta M; Abou-Seri SM; Abdel-Aziz HA
Future Med Chem; 2018 Dec; 10(24):2771-2789. PubMed ID: 30526032
[TBL] [Abstract][Full Text] [Related]
14. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction (MDM2 Inhibitors) in clinical trials for cancer treatment.
Zhao Y; Aguilar A; Bernard D; Wang S
J Med Chem; 2015 Feb; 58(3):1038-52. PubMed ID: 25396320
[TBL] [Abstract][Full Text] [Related]
15. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
Wang W; Hu Y
Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
[TBL] [Abstract][Full Text] [Related]
16. Targeting the MDM2-p53 Protein-Protein Interaction for New Cancer Therapy: Progress and Challenges.
Wang S; Zhao Y; Aguilar A; Bernard D; Yang CY
Cold Spring Harb Perspect Med; 2017 May; 7(5):. PubMed ID: 28270530
[TBL] [Abstract][Full Text] [Related]
17. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
Millard M; Pathania D; Grande F; Xu S; Neamati N
Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
[TBL] [Abstract][Full Text] [Related]
18. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer.
Patel S; Player MR
Expert Opin Investig Drugs; 2008 Dec; 17(12):1865-82. PubMed ID: 19012502
[TBL] [Abstract][Full Text] [Related]
19. Computational analysis of spiro-oxindole inhibitors of the MDM2-p53 interaction: insights and selection of novel inhibitors.
Huang W; Cai L; Chen C; Xie X; Zhao Q; Zhao X; Zhou HY; Han B; Peng C
J Biomol Struct Dyn; 2016; 34(2):341-51. PubMed ID: 25808617
[TBL] [Abstract][Full Text] [Related]
20. The role of p53 in cancer drug resistance and targeted chemotherapy.
Hientz K; Mohr A; Bhakta-Guha D; Efferth T
Oncotarget; 2017 Jan; 8(5):8921-8946. PubMed ID: 27888811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
